Since their approval in 2005, some clinicians have been cautious about prescribing GLP-1 receptor agonists (GLP-1 RAs), or weight loss drugs, to patients with very high triglycerides due to their elevated pancreatitis risk
Check out our free eBook, which will help you better understand the kinds of health enhancements you may make in your regular life.
For patients with type 2 diabetes, stopping GLP-1 therapy without alternative glucose-lowering medication typically results in worsening glycemic control
Mounjaro: A Dual-Hormone Approach Mounjaro is already approved and widely used for weight loss and diabetes management
External resources New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) JAMA: SURMOUNT-4 Continued Treatment With Tirzepatide for Maintenance of Weight Reduction JCI Insight: Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist For researchers serious about optimizing their tirzepatide protocol, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions
[Google Scholar] 52.Maquart F.-X., Bellon G., Chaqour B., Wegrowski J., Patt L.M., Trachy R.E., Monboisse J.-C., Chastang F., Birembaut P., Gillery P
